You are here

KBP Biosciences

Novo seeks $830M in fraud case against Singaporean biotech over kidney drug

BioSpace

Tue, 02/18/25 - 11:13 am

KBP Biosciences

Novo Nordisk, with coffers filling with cash, buys rival to Bayer's kidney drug Kerendia in $1.3B deal

Fierce Biotech

Mon, 10/16/23 - 10:24 am

KBP Biosciences

chronic kidney disease